Finally, given the strong anti-neoplastic effect induced by FASN depletion in AKT/c-Met mouse livers and the molecular mechanisms involved, we assessed the frequency of HCC patients who might eventually benefit from FASN inhibition. The gene discussed is FASN; the disease is hepatocellular carcinoma.